Dengue & Chikungunya In Asia Strategies for Testing

Sally Lam Blood Services Group Health Sciences Authority Singapore

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

The Viruses - Arboviruses

DENGUE
Flavivirus Enveloped virus, ~50 nm in diameter with single-stranded RNA, ~10.7 kb in length 4 serotypes based on immunological properties (DEN-1, DEN-2, DEN-3 & DEN-4) Mainly maintained in urban cycle :

CHIKUNGUNYA
Alphavirus Enveloped virus, spherical particle, 60-70 nm in diameter, single-stranded RNA, ~11.8 kb length 3 lineages from phylogenetic analysis : West Africa; Asia; East, Central & South African (ECSA) Mainly maintained in sylvatic cycle :

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

The Vector

DENGUE

CHIKUNGUNYA
Vectors : Aedes aegypti and Aedes albopictus Prefers outdoor environment - suburban, forests Opportunistic feeding on wide range of hosts Breeds in both natural and artificial containers Dispersal even more widespread than Ae aegypti

Primary vector : Aedes aegypti mosquito Highly domesticated, prefers to rest indoors Predominantly daytime feeder, peak biting activity at dawn and dusk Prefers to breed in artificial containers Multiple feeding within a single blood meal, with preference for human host, infected mosquitoes may take longer to complete blood meal
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

The Disease Onset

DENGUE
Homologous immunity to single serotype complete and lifelong, cross-protection between serotypes lasts less than 12 weeks Primarily diseases of children High fever, serve headache, pain behind the eyes, muscle & joint pains and rash. Clinical Illness : undifferentiated fever; dengue fever (DF); dengue hemorrhagic fever (DHF) & dengue shock syndrome (DSS) DSS is a medical emergency associated with high mortality rate and DIC, requires intensive blood transfusion support. Supportive treatment only
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

CHIKUNGUNYA
Single serotype - life long immunity High fever rapidly emerges associated with headache, back pain, myalgia & intense joint pain Fatalities rare, 1:1000 cases classied as severe, - elderly, pregnant women, immunosuppressed patients at risk majority do not require blood transfusion Treatment symptomatic

Average Annual Number of DF/DHF Cases Reported to WHO & Average Number of Countries Reporting Dengue

 Since 1970s leading cause of hospitalization and death in children in SEA Of those at risk, >70% in the Region Even temperate countries are affected e.g. Bhutan, Nepal

Hyperendemic for Dengue : Singapore

DENV-1

DENV-2

Lab-based dengue surveillance of dengue patient samples from TTSH from 2005 2008. *10% of all dengue cases.
Source : Emerging Infectious Diseases, Vol 16, No. 5, May 2010

1958 Bangkok

1963 India
1998 Malaysia 2001 Indonesia ~ mainly Asian strains with small outbreaks

A226V variant of ECSA for 08/09 outbreak found in Thailand, Malaysia, Singapore, Bangladesh, Taiwan

Asian genotype

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

Aggressive vector control & active case detection/isolation of patients

Ae. Albopictus Suburban residential areas A226V variant Ae. Aegypyti Urban areas ECSA type

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

Factors Contributing to Expansion

Convenient global travel Population growth Urbanization Low or no herd immunity Changes in weather patterns Inadequate water management Lack of effective mosquito control Increasing rate of viral genetic change and emergence of strains/genotypes with greater epidemic potential

Transmission of DEN/CHIK by Blood Transfusion

2 documented cases (Hong Kong & Singapore) for Dengue by blood transfusion, viral load not determined. No reports of transfusion transmission from CHIKV.

Reunion Island 2005- 2006 epidemic peak : 2 out of 568 blood donors RT-PCR positive. One donor was in presymptomatic phase of infection, the other never developed symptoms
Singapore 2008 outbreak : Active CHIK surveillance using RT-PCR, 2 viremic cases founded 1 day before onset of illness. Viral load level were 40 pfu/mL and 750 pfu/mL respectively. Estimated risk of viremic blood donation was high in endemic countries, but low compared to the risk of mosquito-borne DEN/CHIKV transmission.
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

11

Strategies for Testing

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

12

Dengue Diagnosis: Primary infection

Incubation Disease
IgM Intrinsic Viremia IgA IgG 15 20 Days

Recovery

FEVER
-7 0 1 5 7 8

Tests for

Viraemic/Fever phase
Tests for Seroconversion

- Virus isolation - NAT Detect NS1 Ag

IgM ELISA / duo cassette IgG ELISA

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

13

Tests for Viremic/Fever Phase : Dengue

TMA (Gen-Probe)
Transfusion 2008; 48:1355-1362, Linnen et al Analytical sensitivity : 95% detection limit of 14.9 copies/ml 50% detection limit of 3.5 copies/ml. Detects all 4 serotypes at 0.11 PFU/ml. Single donation testing required.

Multiplex RT-PCR J. Clinical Microbiol 2006. 45:935-941, Lai et al.

use of SYBR Green for detection of all four DENV serotypes and fluorogenic probebased (FRET) for DENV serotyping Detects 0.1 PFU/ml for DEN 1-3; 0.01 PFU/ml for DEN-4 88% positive correlation between virus isolation and RT-PCR with regard to dengue virus detection Single donation testing required.
5/26/2010
14
All Rights Reserved 2008 Health Sciences Authority

Tests for Viremic/Fever phase : Dengue

NS1 antigen assays
NS1 membrane/secreted NS1, secreted NS1 could be detected

at day 1-9 after fever onset; surrogate marker of dengue viremia. 2 platforms by Biorad : ELISA & lateral flow rapid test (strip) test sensitivity : 97.3% for Primary Infection; 70% for Secondary Infection (Kumarasamy et al, 2007) NS1 more sensitive than EHI multiplex PCR (72.5%) A negative test does not exclude recent infection
Biotin Bound Antiden NS1 Ig Gold particles coated with streptavidin Capillary action

Platelia Dengue NS1 Ag assay -FDA allows IND for blood screening (May 2010)
Ms Anti-NS1 Mab -HRP

Serum
Ms Anti-den NS1 Mab

Diluted serum
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

Unbound gold labeled antiden NS1 Ig

Biorad NS1 Ag detection platform 15

Chikungunya Diagnosis
Incubation Disease
IgM Intrinsic Viremia IgA IgG 15 20 Days

Recovery

FEVER
-7 0 1 4 7 8

Tests for

Viraemic/Fever phase
Tests for Seroconversion

- Virus isolation - NAT

Euroimmun IFT IgM/IgG

In-house IgG Dot Blot

Virus Neutralisation assay

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

16

Tests for Viremic/Fever phase : Chikungunya

RT-PCR
Good & Definitive test Most conclusive

useful for initial viremic phase

(day 0 day 7) Used in active surveillance during the Singapore outbreak No Antigen tests available.

Adapted protocols with EHI in-house evaluation 1. Hasebe F et al. Combined Detection and Genotyping of CHIKV by a Specific Reverse TranscriptionPolymerase Chain Reaction. Journal of Medical Virology 67:370 374 2002 -

Detection limit of 100 pfu/ml. Though is less sensitive, 2 cases were detected as PCR positive 1 day before onset of fever

2. Pastorino B et al., 2005. Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African CHIKV. Journal of Virological Methods 124. 2005. 65 71.

Taqman probe, very sensitive method, detection limit of 0.1 pfu/ml (Protocol kindly provided by Dr Tim Barkham, TTSH) 5/26/2010
All Rights Reserved 2008 Health Sciences Authority

17

Stratification of Countries
Category A - major public health problem, leading cause of hospitalization and death among children, cyclical epidemics in urban areas, spreading to rural areas, multiple circulating serotype Category B - cyclical epidemics becoming more frequent, multiple circulating serotypes, expanding geographically within country Category C - endemicity uncertain Category D - no evidence of endemicity

Strategies No Specific Measures

Endemic Countries
Risk of DEN/CHIK TTI increased, dependant on prevalence in donor population, and proportion of donors with asymptomatic infection. No direct cost to blood service indirect cost from patient morbidity from TTIs loss of confidence in blood supply safety.

Non-Endemic Countries
Risk of DEN/CHIK TTI low, depends on donor population exposure through travel. No direct cost to blood service indirect cost from loss of confidence in blood supply safety in event of a TTI occurring.

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

19

Strategies - Donor Qualification Deferral

Endemic Countries
Deferral based on exposure not feasible when disease is endemic. Unable to exclude early and asymptomatic infection. Non-specific, leads to high donor loss. Low cost effectiveness.

Non-Endemic Countries
Deferral based on exposure feasible, able to reduce risk of accepting donations from early and asymptomatic infected donors. Low donor loss, dependant on proportion of donor population likely to travel to endemic countries. Cost effective.

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

20

Strategies Testing by NAT / Ag

Endemic Countries
Able to detect asymptomatic infection. Donor loss dependant on specificity of test system. Universal testing. NAT - Expensive. Antigen testing affordable. Cost effectiveness depends on prevalence of asymptomatic infected donors.

Non-Endemic Countries
Able to detect asymptomatic infection. Donor loss dependant on specificity of test system. Selective testing. NAT - Expensive. Antigen testing affordable. Low cost effectiveness.

Singapore BSG conducted a donor prevalence study, 5,204 donations (2006 2007) screened by DEN Fourplex RT-PCR (Lanciotti et al, 2005), no cases detected. No licensed NAT / Ag assays for blood donation screening
5/26/2010 diagnostic tests need to be validated for blood screening prior to use.
All Rights Reserved 2008 Health Sciences Authority

21

Strategies - Pathogen Reduction

Endemic Countries
Able to reduce transmission risks. Expensive and only available for platelets and plasma currently. May result in reduced product yields. Increased cost effectiveness depends on ability to reduce risks of other TTDs as well.

Non-Endemic Countries
Able to reduce transmission risks. Expensive and only available for platelets and plasma currently. May result in reduced product yields. Increased cost effectiveness depends on ability to reduce risks of other TTDs as well.

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

22

Evaluation of the INTERCEPT and Mirasol PR Systems on the Inactivation of DENV-2 and CHIKV in Single-Donor Platelet Concentrates Blood Services Group, Health Sciences Authority; Environmental Health Institute, National Environment Agency

APLT suspended in 100% plasma 4 sets of double APLT used for each virus study (3 test and 1 control) screened for DENV/CHIKV virus and antibodies
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

23

DENV-2 Inactivation - Plaque Assay

INTERCEPT
SDP sample 294 (I) Pre-treatment Virus Titre (log pfu/ml) 3.71 Post-treatment Virus Titre (log pfu/ml) Day 1 ND Day 3 ND Day 5 ND Day 7 ND Log-reduction >6.12

306 (I)
319 (I) 292 (I) ctrl

1.7
2.44 2.3

ND
ND 2.3

ND
ND ND

ND
ND ND

ND
ND ND

>4.11
>4.85 0

Mirasol
SDP Sample 294 (M) Pre-treatment Virus Titre (log pfu/ml) 3.46 Post-treatment Virus Titre (log pfu/ml) Day 1 1.88 Day 3 ND Day 5 ND Day 7 ND Log-reduction 1.58

306 (M)
319 (M) 292 (M) ctrl

1.88
2.76 2.95

ND
2 2.54

ND
ND ND

ND
ND ND

ND
ND ND

>4.29
0.76 0.41

ND: not detected. >, inactivation to below the limit of detection. No virus was detected in the volume assayed.

CHIKV Inactivation - Plaque Assay

INTERCEPT
SDP sample 897 907 909 888 (ctrl) Pre-treatment Virus Titre (log pfu/ml) 4.4 4.36 4.45 4.63 Post-treatment Virus Titre (log pfu/ml) Day 1 ND ND ND not collected Day 3 ND ND ND 4.15 Day 5 ND ND ND 3.36 Day 7 ND ND ND 3.2 Log-reduction >6.81 >6.78 >6.86 Day 3: 0.49 Day 5: 1.27 Day 7: 1.43

Mirasol
SDP sample 897 907 909 888 (ctrl) Pre-treatment Virus Titre (log pfu/ml) 4.34 4.43 4.4 4.52 Post-treatment Virus Titre (log pfu/ml) Day 1 ND ND ND 4.04 Day 3 ND ND ND 3.46 Day 5 ND ND ND 3.36 Day 7 ND ND ND 3.18 Log-reduction >6.76 >6.85 >6.81 Day 1: 0.48 Day 3: 1.06 Day 5: 1.16 Day 7: 1.34

ND: not detected. >, inactivation to below the limit of detection. No virus was detected in the volume assayed.

Determining Appropriate Measures for Blood Supply

Prevalence of infection in population Prevalence of infection in donor population Effectiveness of existing strategies Effectiveness/availability of testing/ pathogen reduction Impact on blood supply availability Clinical importance in transfusion recipients Cost effectiveness in reducing disease morbidity in relation to overall health situation in the country
5/26/2010
All Rights Reserved 2008 Health Sciences Authority

26

Acknowledgment

Dr Diana Teo Group Director , Blood Services Group, Health Sciences Authority Dr Ng Lee Ching Head, Environmental Health Institute, National Environmental Agency Dr Tan Li Kiang Research Scientist, Environmental Health Institute, National Environmental Agency

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

27

Thank You

5/26/2010
All Rights Reserved 2008 Health Sciences Authority

28